发表于 2023-2-4 17:18:07
来源:http://www.bbs22.cn
The BOLERO 2 study showed an improvement in response rates and progression free survival with the addition of Everolimus, an mTOR inhibitor to Exemestane in metastatic ER positive breast cancer after failure on a non steroidal AI <a href=http://vkamagras.cyou>online kamagra</a> Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG |
|